Jefferies Remains a Buy on Bellicum Pharmaceuticals

By Austin Angelo

Jefferies analyst Biren Amin reiterated a Buy rating on Bellicum Pharmaceuticals (NASDAQ: BLCM) on September 12 and set a price target of $16. The company’s shares opened today at $10.34.

According to, Amin is a 5-star analyst with an average return of 11.4% and a 51.1% success rate. Amin covers the Healthcare sector, focusing on stocks such as DBV Technologies SA – American, Iovance Biotherapeutics Inc, and Stemline Therapeutics Inc.

Bellicum Pharmaceuticals has an analyst consensus of Strong Buy, with a price target consensus of $21.67.

Based on Bellicum Pharmaceuticals’ latest earnings report for the quarter ending June 30, the company posted quarterly revenue of $0 and GAAP net loss of $24.46 million. In comparison, last year the company earned revenue of $101K and had a GAAP net loss of $16.51 million.

TipRanks has tracked 36,000 company insiders and found that a few of them are better than others when it comes to timing their transactions. See which 3 stocks are most likely to make moves following their insider activities.

Bellicum Pharmaceuticals, Inc. is a clinical stage biopharmaceutical company, which focuses on discovering and developing cellular immunotherapies for cancers and orphan inherited blood disorders. It’s proprietary chemical induction of dimerization technology engineers and controls components of the immune system. The company was founded by Kevin M.